Cmv-specific T Cells
Cmv-specific T Cells - Related Videos
10:24
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
0 Views •
Cited by 23 •
2015
The goal of this protocol is to manufacture pathogen-specific clinical-grade T cells using a bench-top, automated, second generation cell enrichment device that incorporates a closed cytokine capture system and does not require dedicated staff or use of a GMP facility. The cytomegalovirus pp65-specific-T cells generated can be directly administered to patients.
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
0 Views •
Cited by 49 •
2011
A rapid, simple and cost-effective protocol for the generation of donor-derived multivirus-specific CTLs (rCTL) for infusion to allogeneic hematopoietic stem cell transplant (HSCT) recipients at risk of developing CMV, Adv or EBV infections. This manufacturing process is GMP-compliant and should ensure the broader implementation of T-cell immunotherapy beyond specialized centers.
01:58
Cell Specific Gene Expression
0 Views •
2020
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
11:55
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
0 Views •
Cited by 9 •
2011
This paper describes a simple technique to induce alloantigen-specific anergy in human peripheral blood mononuclear cells. The technique can be applied clinically to generate non-alloreactive donor cells. Infusion of these cells could improve immune reconstitution and reduce toxicity after allogeneic hematopoietic stem cell transplantation.
10:15
Isolation and Culture Expansion of Tumor-specific Endothelial Cells
0 Views •
Cited by 20 •
2015
We report a reliable method to isolate and culture primary tumor-specific endothelial cells from genetically engineered mouse models.
FAQs
Recognition begins when CMV proteins are processed into smaller peptides and displayed on major histocompatibility complex molecules. This presentation gives T cells the molecular information needed to distinguish CMV-related targets from other signals. The resulting response can include direct elimination of infected cells by CD8+ T cells and coordinated immune activity supported by CD4+ T cells.
CD8+ T cells contribute a direct effector function by killing cells that display relevant CMV peptides. CD4+ T cells contribute through cytokine production and support for coordinated antiviral immunity. Considering both populations is important because CMV control depends not only on removing infected cells, but also on organizing broader immune activity around the antiviral response.
Antigen specificity allows a cellular therapy to focus immune activity on CMV-related targets rather than broadly activating the immune system. This principle supports therapies intended to restore antiviral defense in situations where protection is limited. It also connects the biological recognition process with a practical design goal: directing treatment toward CMV without unnecessarily stimulating unrelated immune responses.
Measuring CMV-specific T cell responses provides information about antiviral immune protection rather than relying only on the presence of infection. The overview identifies this assessment as particularly relevant for transplant recipients and immunocompromised patients, who may need evaluation of their ability to control CMV. These measurements can therefore inform understanding of immune competence in vulnerable settings.
These patient groups are emphasized because their CMV-related immune protection is clinically important to evaluate. Assessing CMV-specific T cell responses can help characterize the antiviral defenses available in individuals whose immune systems may not provide adequate control. The information is especially relevant when considering the risk associated with CMV infection or reactivation in settings of impaired immunity.
Their defined recognition of CMV antigens provides a basis for designing cellular therapies aimed at restoring antiviral defense. The therapeutic objective is not simply to increase immune activity generally, but to use CMV-directed recognition to address the relevant viral threat. This approach links peptide presentation and T cell function with applications intended for patients needing renewed protection against CMV.